Figure - available from: Evidence-based Complementary and Alternative Medicine
This content is subject to copyright. Terms and conditions apply.
(a) Venn diagram. 481 genes are coregulated by BYHW, NXT, and YYTN. There are 146 genes specifically regulated by BYHW; 107 genes are specifically regulated by NXT and 172 genes are specifically regulated by YYTN. (b–e) Analysis of protein interaction network by STRING. The first 30 genes of BYHW specifically regulated are shown in (b). The first 30 genes of NXT specifically regulated are shown in (c). The first 30 genes of YYTN specifically regulated are shown in (d). The first 30 coexpressed genes of BYHW, NXT, and YYTN are shown in (e). (f–i) Heatmaps of correlation between characteristic intestinal flora and key genes. (f) BYHW-based heatmap; (g) NXT-based heatmap; (h) YYTN-based heatmap; (i) BYHW, NXT, and YYTN-based heatmap.
Source publication
Background:
The traditional Chinese medicines of Buyang Huanwu decoction (BYHW), Naoxintong capsule (NXT), and Yangyin Tongnao granules (YYTN) have excellent effects in preventing and treating cerebrovascular disease and are widely tolerated by patients. However, their effects on middle cerebral artery occlusion (MCAO) remain unknown.
Methods:
W...
Citations
Ethnopharmacological relevance:
Buyang Huanwu decoction (BHD), a famous traditional Chinese medicine (TCM) formula, was first recorded in Qing Dynasty physician Qingren Wang's Yi Lin Gai Cuo. BHD has been widely utilized in the treatment of patients with neurological disorders, including Parkinson's disease (PD). However, the underlying mechanism has not been fully elucidated. In particular, little is known about the role of gut microbiota.
Aim of the study:
We aimed to reveal the alterations and functions of gut microbiota and its correlation with the liver metabolome in the process of improving PD with BHD.
Materials and methods:
The cecal contents were collected from PD mice treated with or without BHD. 16S rRNA gene sequencing was performed on an Illumina MiSeq-PE250 platform, and the ecological structure, dominant taxa, co-occurrence patterns, and function prediction of the gut microbial community were analyzed by multivariate statistical methods. The correlation between differential microbial communities in the gut and differentially accumulated metabolites in the liver was analyzed using Spearman's correlation analysis.
Results:
The abundance of Butyricimonas, Christensenellaceae, Coprococcus, Peptococcaceae, Odoribacteraceae, and Roseburia was altered significantly in the model group, which was by BHD. Ten genera, namely Dorea, unclassified_Lachnospiraceae, Oscillospira, unidentified_Ruminococcaceae, unclassified_Clostridiales, unidentified_Clostridiales, Bacteroides, unclassified_Prevotellaceae, unidentified_Rikenellaceae, and unidentified_S24-7, were identified as key bacterial communities. According to the function prediction of differential genera, the mRNA surveillance pathway might be a target of BHD. Integrated analysis of gut microbiota and the liver metabolome revealed that several gut microbiota genera such as Parabacteroides, Ochrobactrum, Acinetobacter, Clostridium, and Halomonas, were positively or negatively correlated with some nervous system-related metabolites, such as L-carnitine, L-pyroglutamic acid, oleic acid, and taurine.
Conclusions:
Gut microbiota might be a target of BHD in the process of ameliorating PD. Our findings provide novel insight into the mechanisms underlying the effects of BHD on PD and contribute to the development of TCM.
Background:
Cerebral ischemia-reperfusion (CIR) injury occurs as a secondary injury during the treatment of ischemic stroke (IS). There is a high death rate and morbidity due to IS throughout the world. Even though Naoxintong Capsule (NXT) is effective in the treatment of CIR, its mechanisms of action are unclear.
Purpose:
The study aims to explore the clear mechanism associated with NXT therapy for CIR.
Methods:
We established the model of middle cerebral artery occlusion (MCAO) to evaluate the neurological function and assess the infarct size. Brain tissue metabolomics was used to identify different metabolites, and metabolic profiling systems enriched metabolic pathways. Then, the potential targets of NXT in the treatment of CIR were explored by proteomic, transcriptomic and metabolomic methods.
Results:
NXT improves CIR Symptoms. We found potential 11 proteins and corresponding metabolites involved in NXT treatment of CIR. Most of these metabolites are regulated to restore after treatment. According to network pharmacology, we found 6 hub genes including Glb1, Gmps, Pfas, Atic, Gaa and Acox1, and their associated core metabolites and pathways.
